The project’s competitive advantage lies in its targeted, plant-derived senolytic approach that selectively removes aged and dysfunctional vascular cells while preserving healthy cells. Unlike conventional therapies that primarily manage symptoms, this solution addresses the underlying mechanisms of vascular ageing by reducing cellular senescence, inflammation, and arterial deterioration. Its natural origin, non-invasive therapeutic potential, and ability to support long-term cardiovascular health provide a promising advantage in the development of next-generation anti-ageing and cardiovascular interventions.

‍

The accumulation of aged and damaged vascular cells contributes to inflammation, arterial stiffening, and the progression of cardiovascular diseases. Current treatments often do not directly address the underlying cellular ageing process, creating a need for a safe and targeted therapeutic approach to restore vascular health, improve blood flow, and reduce age-related cardiovascular risks.

‍

The project develops a plant-derived senolytic therapeutic agent that selectively targets and eliminates aged or damaged endothelial cells while preserving healthy vascular cells. By reducing cellular ageing and inflammation within blood vessels, the solution aims to improve vascular function, enhance blood flow, prevent arterial deterioration, and support long-term cardiovascular health through a safe, targeted, and non-invasive approach.

‍

The project introduces a novel plant-derived senolytic therapeutic agent that harnesses natural compounds to selectively eliminate senescent vascular cells without harming healthy cells. This targeted approach offers a new strategy for addressing vascular ageing by tackling the underlying cellular causes of cardiovascular decline, providing a safer and more precise alternative to conventional treatment approaches.

‍